Fanapt revenue growth of 24% was primarily driven by a 149% surge in new-to-brand prescriptions following the bipolar disorder commercial launch. Management attributes accelerating Fanapt momentum to targeted commercial investments, including direct-to-consumer campaigns and a sales force expansion to approximately 300 representatives. HETLIOZ revenue declined 7% due to generic competition, though the product has retained the majority of market share after three years of generic entry. The approval ...